Introduction
Obesity, as the result of antipsychotic-induced weight gain, is an important adverse effect of antipsychotic drugs. 1 Patients with overweight have, among others, an increased risk of diabetes mellitus, hypertension and cardiovascular disease and subsequently a higher risk of mortality. 2, 3 In addition, psychiatric patients themselves consider weight gain as one of the most disturbing adverse events: it is an important reason for non-compliance 4 and for switching atypical antipsychotics in daily psychiatric practice. 5 The risk of antipsychotic-induced weight gain and obesity appears to be high for atypical antipsychotics, especially clozapine and olanzapine. 1 The mechanism behind antipsychotic-induced weight gain is not entirely clear. The high interindividual variability suggests that genetic make-up is a modulating factor. One of the potential genetic determinants of antipsychotic-induced weight gain and obesity is the genetic variation in the serotonin 2C (5-HT2C) receptor encoded by the HTR2C gene.
Yuan et al. 6 found that several polymorphisms in the promoter region of the HTR2C gene were associated with an increased risk of diabetes and obesity in patients without psychiatric disorders. Subsequent studies into the association between antipsychotic-induced weight gain or obesity and HTR2C genotype for one of these polymorphisms (À759 C/ T; a single-nucleotide polymorphism (SNP) with dbSNP database (www.ncbi.nlm.nih.gov/SNP) identifier rs3813929) reported conflicting results. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Reynolds et al. [7] [8] [9] and Ellingrod et al. 10, 11 found a positive association between the HTR2C rs3813929:C4T (À759 C/T) genotype and antipsychotic-induced weight gain and Pooley et al. 17 found a positive association with obesity in females without psychiatric disorders. Other studies could, however, not confirm the association. 12, 14, 15, 18 Furthermore, one of these studies 18 could not find the association between the rs3813929:C4T genotype and obesity, but did find an association between a promoter haplotype and obesity in a population without psychiatric disorders. The objective of this cross-sectional study was to evaluate whether polymorphisms in the promoter region of the HTR2C gene (HTR2C:c.1-142948(GT) n , rs3813928 (À997 G/A), rs3813929 (À759 C/T), rs518147 (À697 G/C)) and an intragenic polymorphism (rs1414334:C4G) in intron 5 close to the HTR2C 3 0 untranslated region (UTR), which has never been studied before in this context, are associated with obesity in psychiatric patients using antipsychotics.
Results
In total, 138 hospitalized (n ¼ 36) and non-hospitalized (n ¼ 102) psychiatric patients with chronic psychiatric disorders gave informed consent for participation in this study. Body mass index (BMI) or other relevant information was not available for 11 patients. Therefore, the study population consisted of 127, mainly, Caucasian (495%) patients with a mean age of 37 (s.d. 11). Sixty-three per cent (n ¼ 80) was male. The included patients were diagnosed with schizophrenia or schizoaffective disorder in 62% (n ¼ 79) and 26% (n ¼ 33), respectively.
The most frequently used antipsychotics were clozapine (n ¼ 44 (35%)), olanzapine (n ¼ 40 (32%)) and risperidone (n ¼ 26 (21%)). Other antipsychotics used were aripiprazole
Polypharmacy was present in 19 (15%) of the included patients.
Genotype distribution of the polymorphisms analysed in this study did not deviate significantly from Hardy-Weinberg equilibrium (HWE) (HTR2C:c.1-142948(GT) n (P40.1), rs3813928 (À997 G/A) ¼ rs3813929 (À759 C/T) (P ¼ 0.1888), rs518147 (À697 G/C) (P ¼ 1.0) and rs1414334:C4G (P ¼ 1.0)).
The complete linkage disequilibrium (LD) (r 2 ¼ 1) between the rs3813928 (À997) A allele and the rs3813929 (À759) T allele as described previously 6 was confirmed in this study. The rs518147 C allele and the HTR2C:c.1-142948(GT) n 13 repeat allele were in complete LD as well. LD (r 2 ) for other SNP pairs is shown in Table 3 . For the rs1414334 polymorphism allele, C is described as the ancestral allele (dbSNP database; www.ncbi.nlm.nih.gov/SNP). However, in Western and Northern Europeans, allele G appears to be the major allele, which is confirmed in this study. In the analysis, we therefore considered the allele C as the variant allele. For the HTR2C:c.1-142948(GT) n repeat polymorphism, five alleles were detected with 13, 15, 16, 17 and 19 repeats, respectively. Genotypes with the alleles 15, 17 and 19 repeats were rare (n ¼ 8 (6%)). Therefore, the outcome measures were calculated only for carriers of the alleles with 13 and 16 repeats (n ¼ 119 (94%)), with the 13 repeat allele defined as the variant allele. Because of the differences in the number of patients, the results of the HTR2C:c.1-142948(GT) n and the rs518147 (À697 G/C) polymorphism are presented separately. The characteristics of the included patients are summarized in Table 4 There was no association between obesity (P40.20) and the covariates type of antipsychotic drugs used, dosage (prescribed daily dose (PDD)) of the antipsychotic drugs used, use of weight-reducing drugs and whether the patient was hospitalized or not. Accordingly, the obtained results were adjusted for age, gender, polypharmacy, use of weight gain-inducing drugs and use of glucose-lowering drugs. The interaction term for carriership of a variant HTR2C allele and gender was not significant (P40.50). Figure 1 shows that the association between HTR2C genotypes and BMI was not significant. However, a trend towards increased BMI was seen for carriers of the variant rs1414334 allele C in intron 5 of the HTR2C gene compared to patients with the common genotype. Table 6 shows that the combined genotype carrying the variant HTR2C:c.1-142948(GT) n 13 repeat allele, the common allele rs3813929 (À759) C, the variant allele rs518147 (À697) C and the variant allele rs1414334 C was significantly associated with an increased risk of obesity (OR 3.71 (95% CI: 1.24-11.12)) compared to the combined genotype without variant alleles.
Discussion
In this cross-sectional study, the rs1414334:C4G polymorphism in intron 5 of the HTR2C gene and the combined genotype of the variant 13 repeat allele for HTR2C:c.1-142948(GT) n , the common allele rs3813929 (À759) C, the variant allele rs518147 (À697) C and the variant allele rs1414334 C were found to be associated with an increased risk of obesity in patients using antipsychotics.
There are some limitations to these results. Firstly, we recognize that the power of our study was limited. The small sample size may have limited the power to detect differences between groups that are only moderate in size. We did not adjust the P-value to the number of tests owing to power considerations because this could increase the type II error rate too much. The limited sample size resulted in several nonsignificant point estimates in the adjusted analyses, although the point estimates of the, quite conservatively, adjusted analyses remained in the same order of magnitude compared to the univariate analyses making a type I error highly unlikely. 19 However, in answer to these limitations, it is important that these results are confirmed in a larger sample of patients. Secondly, data on BMI of the patients at the initiation of antipsychotic drug treatment were not available to us. Therefore, it was not possible to analyse data for changes in weight over time related to the use of antipsychotic drugs. This limitation makes it difficult to compare our results to other studies that investigated the association between weight gain and the HTR2C rs3813929:C4T (À759 C/T) polymorphism in psychiatric patients using antipsychotics. It is possible that we did not find significant results for the HTR2C rs3813929:C4T (À759 C/T) polymorphism due to this limitation. Thirdly, apart from genotype several other variables can contribute to the risk of weight gain and obesity. For example, smoking behaviour, diet and exercise were not taken into account. However, these variables probably do not influence the results because these variables most likely have the same distribution in different genotype groups.
To our knowledge, this is the first study that investigated the association between obesity in psychiatric patients using antipsychotics and the HTR2C:c.1-142948 (GT) n dinucleotide polymorphism and the rs518147:G4C (À697 G/C) SNP, both located in the HTR2C promoter region, and the intragenic SNP rs1414334:C4G in intron 5 of the HTR2C gene close to the 3 0 UTR. The association between HTR2C genotype and diabetes and obesity in Japanese men without psychiatric disorders by Yuan et al. 6 was the starting point for several studies investigating the association between HTR2C genotype in patients using antipsychotics. Yuan et al. 6 showed significant associations between obesity and type II diabetes and the linked rs3813928:G4A (À997 G/A) and rs3813929:C4T (À759 C/T) polymorphisms, but these associations were found for the HTR2C:c.1-142948(GT) n repeat and the rs518147:G4C (À697 G/C) polymorphisms as well. The association between obesity and the rs3813928: G4A polymorphism was confirmed in female patients without psychiatric disorders, but another study could only find a positive association between obesity and a promoter haplotype also in patients without psychiatric disorders. 17, 18 Reynolds et al. 7, 8 were the first to report a positive association between rs3813929:C4T (À759 C/T) genotype and weight gain in Chinese Han patients using different kinds of antipsychotics but also in patients using clozapine, but they did not investigate the other polymorphisms (HTR2C: c.1-142948(GT) n , rs3813928:G4A (À997 G/A) and rs518147:G4C (À697 G/C)) reported by Yuan et al.
The possible high impact of these data for psychiatric practice resulted in several publications trying to replicate these results. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The results of Reynolds et al. were confirmed in several studies, [9] [10] [11] but other studies could not confirm these findings. 12, 14, 15 This was suggested to be due to the LD with another (causative) variant that might co-segregate differently in different ethnic groups. The confusion regarding the association of different promoter polymorphisms and the possible impact of findings for psychiatric patients taking antipsychotics made us to decide to analyse all the promoter polymorphisms reported by Yuan et al., and furthermore to study an additional frequent intragenic SNP within intron 5 of the HTR2C gene, close to the 3 0 UTR. We could confirm that also in a European Caucasian population, the rs3813928 (À997) A allele and the rs3813929 (À759) T allele are in complete LD. We could not confirm the association of carriership of the 13 repeat allele of the HTR2C:c.1-142948(GT) n repeat polymorphism or the variant alleles rs3813928 (À997) A , rs3813929 (À759) T and rs518147 (À697) C with a BMI below 28 kg/m 2 found by Yuan et al. We found results in the opposite direction with an increased risk of obesity (BMI 430 kg/m 2 ) in patients carrying the variant alleles (results did not change significantly when the cutoff point for BMI was chosen at 28 kg/m 2 ). The association between obesity and HTR2C genotype looks particularly strong for the intragenic SNP rs1414334 not reported previously. Discordance of observed associations between HTR2C promoter polymorphisms and obesity compared to the association between a polymorphism within the HTR2C gene and obesity is not surprising. The substantial genomic distance between the studied promoter polymorphisms and the intragenic SNP (over 300 kb), and the observed incomplete LD across the genomic region flanking and within the HTR2C gene 18 can possibly explain the strength and/or nature of the associations identified. Different factors influencing HTR2C expression, RNA stability or function may have been identified by the intronic SNP compared to those identified by the promoter polymorphisms, which may result in the observation of a different or mixed association pattern. However, as the rs1414334 polymorphism itself does not have an obvious function within the HTR2C gene, other variants in LD with this one should also be investigated. Another explanation for the discordant results could be the possible inverse association between baseline BMI of a patient during initiation of antipsychotic treatment and antipsychoticinduced weight gain. 20 Possibly the variant alleles protect against obesity in subjects without psychiatric disorders but makes them vulnerable to antipsychotic-induced obesity.
Psychiatric patients consider weight gain and the resulting overweight or obesity as one of the most disturbing adverse events and one of the important reasons to become noncompliant. 4 Furthermore, weight gain is one of the important reasons for switching atypical antipsychotics in daily psychiatric practice. 5 These considerations make it important to search for determinants that can predict the risk for antipsychotic-induced obesity before the initiation of antipsychotic drugs. Genotypes of the HTR2C receptor determined before starting pharmacotherapy with antipsychotic drugs possibly are one of these determinants. Patients with an increased risk of obesity are preferably not treated with clozapine or olanzapine. These patients can be treated with antipsychotic drugs with a more favourable weightgain profile. Next to the choice of drug, patients with the 'increased risk genotype' can be stimulated more directly to take part in weight-reducing programmes. Prospective trials are necessary to establish whether HTR2C genotyping results in less weight gain and therefore a reduced risk of becoming obese. Finally, these studies should investigate whether genotyped patients are more compliant to their medication resulting in a lower risk of relapse.
In conclusion, genotypes of HTR2C polymorphisms are associated with the occurrence of obesity in psychiatric patients using antipsychotics. This association appears to be particularly strong in combined genotypes including the variant allele of the intragenic SNP rs1414334. In patients using antipsychotics, choice of drug according to HTR2C genotype could possibly reduce the risk of obesity. Prospective trials are warranted to investigate the clinical value of genotyping the HTR2C polymorphisms before starting antipsychotic drugs in psychiatric patients.
Materials and methods

Setting
Patients were recruited from the Department of Psychotic Disorders of the Mental Health Services Drenthe in the Northern part of the Netherlands. The department consists of several psychiatric services and treats in-and outpatients with schizophrenia and schizoaffective disorder covering a population of approximately 200 000 persons. Patients were identified from a schizophrenia disease management programme developed by the department. Patients taking part in this programme are followed in time by regular standardized evaluation of the patient and measurements of, among others, BMI. All patients treated by services of the department enter the disease management programme sooner or later. For each patient, a prescription file is available listing patient details (age, date of birth, identification), drug details (name of drug and dosage regimen, start and stop date) and treatment details (diagnosis, compliance and adverse events). The study protocol was reviewed and approved by an independent medical ethics committee (METIGG, Utrecht, The Netherlands).
Design and patients
A cross-sectional design was used to assess the relationship between HTR2C variants and obesity in psychiatric patients using antipsychotics. Patients were eligible if they participated in the disease management programme. The antipsychotic drug used during the first evaluation of the patient had to be started at least 3 months before this evaluation. This inclusion criterion was used because weight gain occurs mainly during the first 3 months after the first prescription of the drug. 20 We used this criterion to exclude patients in which antipsychotic-induced weight gain had not yet occurred. After complete description of the study to the patients, written informed consent was obtained. 
Determinants
Primary determinants were genotypes of polymorphisms flanking, or within, the X-linked HTR2C gene. The following polymorphisms in the promoter region were investigated: rs3813928:G4A (À997 G/A), rs3813929:C4T (À759 C/T), rs518147:G4C (À697 G/C) and a (GT) n dinucleotide repeat polymorphism 30 nucleotides further upstream of rs3813928. This dinucleotide polymorphism has no officially designated symbol in variation databases, and will be referred to in this paper as HTR2C:c.1-142948(GT) n . In addition, a frequent SNP in intron 5 of the HTR2C gene close to the 3 0 UTR was investigated (rs1414334:C4G). With regard to HTR2C polymorphism nomenclature, it should be noted that, for reasons of clarity, we use the nomenclature and nucleotide numbering at the genomic level according to the guidelines of the Human Genome Variation Society (HGVS; www.hgvs.org) as well as the 'traditional' nomenclature and numbering used in previous publications. An overview of the polymorphisms indicating their nucleotide numbering according to HGVS guidelines and their numbering used in previous publications is given in Table 1 . Furthermore, in Table 1 the available evidence of the association between the different HTR2C genes and weight gain or obesity is summarized. It should also be noted that in previous publications, the rs3813928:G4A SNP has been erroneously referred to as À995 G/A, instead of À997 G/A (Tables 1-6 ).
HTR2C and obesity H Mulder et al DNA isolation and genotyping by pyrosequencing Genomic DNA was isolated from ethylenediaminetetraacetic acid-anticoagulated peripheral blood using standard methods. The HTR2C genotypes were determined by pyrosequencing, 21 except for the HTR2C:c.1-142948(GT) n polymorphism. 22 The dinucleotide repeat polymorphism Abbreviations: F, forward primer; PCR, polymerase chain reaction; PSQ, pyrosequencing; R, reverse primer. a 6FAM: 6FAM-labelled universal PCR primer sequence used to generate DNA fragments detectable by a charge-coupled device camera during length analysis on a capillary sequencer (ABI3730) subsequent to PCR. Universal sequence in other primer sequences is indicated in bold. Biotin: Biotin-labelled universal PCR primer sequence used to generate DNA fragments for pyrosequencing subsequent to PCR. Universal sequence in other primers is underlined. (Table 2) , 2 U Taq DNA polymerase and 250 ng genomic DNA. The PCR products were biotinylated through the use of a three-primer system during PCR including a universal biotinylated primer. 22 PCR reaction started with a 951C denaturation for 5 min. This was followed by a 40-cycle thermal cycling. Cycling conditions were 30 s denaturation at 951C, 60 s annealing at 551C and a 10 s final extension at 721C. Single-strand biotinylated PCR products were prepared for pyrosequencing. Genotyping was performed in a PSQ96 pyrosequencer according to a protocol of the manufacturer (PyrosequencingAB, Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Pyrosequencing data output was quantified using Peak Height Determination Software v1.1 (PyrosequencingAB). The genotyping results were blinded to the researcher and were not available to the treating psychiatrist before data analysis.
Data analyses and statistics
Pharmacy records and other patient information were transferred to a database (MS Access) for analysis. The Anatomical Therapeutic Chemical (ATC) classification was used to identify antipsychotic (ATC: N05A) drugs. The PDD was defined as the administered dosage divided by the defined daily dose (DDD) (PDD ¼ dosage/DDD) according to The (GT) n repeat was analysed for the most frequent alleles 16 repeat (R) and 13R ( total number of patients n ¼ 119) with 16R as the reference. Sixteen and 13 repeats were the most frequent alleles of the (GT) n polymorphism. In this table, the 13 repeat allele is considered the variant allele. e Data were adjusted for age, gender, polypharmacy, use of weight gain-inducing drugs and use of glucose-lowering drugs. f In total, 13 combinations of genotypes were found only once and were therefore not taken into account in the analysis.
the WHO guidelines. 23 Concomitantly used medication was assessed as being potentially weight-gain inducing, as weight-loss inducing or as having no influence on weight according to the evidence published. 24 Insulins and drugs used to treat diabetes type II were classified as glucoselowering drugs. 25 For all variants, HWE testing was performed. Pairwise LD was analysed using the software program Haploview (version 3.31). 26 The association between BMI and HTR2C genotypes (presence or absence of the variant HTR2C allele) was investigated with univariate analysis of variance. Results were expressed as the mean BMI together with a 95% CI. The risk of being obese was assessed with logistic regression. Results were expressed as an OR together with a 95% CI for carriers of the variant allele compared to the patients with the common allele. Data were investigated for potential confounding effects of age, gender, type and dosage of the antipsychotic drugs used, polypharmacy (more than one antipsychotic drug at the same moment), weight-influencing drugs, glucose-lowering drugs and whether the patient was hospitalized or not. We selected a variable if it was univariately associated with obesity at a significant level of Po0.20.
27 Unless stated otherwise, results are expressed as adjusted OR's. Data were investigated for interaction between carriership of variant alleles and gender. Finally, a combined genotype analysis was performed. In females, combined genotypes were defined as the combinations of individual HTR2C polymorphism genotypes. In males, these co-segregating alleles for the individual polymorphisms are in fact haplotypes. A P-value of 0.05 or less was regarded as significant. No correction for multiple testing was applied. Data were analysed using SPSS 11.0.
